Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes

Drug Testing and Analysis

Volumn 5, Issue 11-12, 2013, Pages 843-849

  Guha, Nishan ^a   Erotokritou Mulligan, Ioulietta ^a   Nevitt, Simon P ^a   Francis, Michael ^a   Bartlett, Christiaan ^b   Cowan, David A ^b   Bassett, E Eryl ^c   Sönksen, Peter H ^a   Holt, Richard I G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Doping; Growth Hormone; IGF I; Markers; Misuse

Indexed keywords

BIOCHEMISTRY; BODY FLUIDS; BONE; INSULIN; RECOMBINANT PROTEINS;

ACID-LABILE; BINDING PROTEINS; GROWTH HORMONES; HUMAN INSULINS; IGFBP-3; INSULIN-LIKE GROWTH FACTOR-I; MARKER; MISUSE; PROCOLLAGEN; PROPEPTIDES;

COLLAGEN;

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; MECASERMIN RINFABATE; OSTEOCALCIN; PROCOLLAGEN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; ATHLETE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSS LINKING; DOPING; DRUG MISUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MALE; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; SPORT; YOUNG ADULT;

DOPING; GROWTH HORMONE; IGF-I; MARKERS; MISUSE;

ADOLESCENT; ADULT; ATHLETES; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; RECOMBINANT PROTEINS; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 84890793025     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1562     Document Type: Article

References (27)

1. World Anti-Doping Agency (WADA). The World Anti-Doping Code: The 2013 Prohibited List International Standard. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2013/WADA-Prohibited-List-2013-EN.pdf [1 March 2013].
2. R.I. Holt Detecting growth hormone abuse in athletes. Anal. Bioanal. Chem. 2011, 401, 449.
3. M. Kohler, A. Thomas, K. Walpurgis, K. Terlouw, W. Schanzer, M. Thevis Detection of His-tagged Long-R(3)-IGF-I in a black market product. Growth Horm. IGF Res. 2010, 20, 386.
4. R.M. Williams, A. McDonald, M. O'Savage, D.B. Dunger Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Exp. Opin. Drug Metab. Toxicol. 2008, 4, 311.
5. D.H. Catlin, A. Breidbach, S. Elliott, J. Glaspy Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin. Chem. 2002, 48, 2057.
6. S. Yokoya, S. Suwa, H. Maesaka, T. Tanaka Immunoreactive somatomedin C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics. Pediatr. Res. 1988, 23, 151.
7. E.F. De Palo, R. Gatti, F. Lancerin, C.B. De Palo, E. Cappellin, G. Solda, P. Spinella Effects of acute, heavy-resistance exercise on urinary peptide hormone excretion in humans. Clin. Chem. Lab. Med. 2003, 41, 1308.
8. R. Dall, S. Longobardi, C. Ehrnborg, N. Keay, T. Rosen, J.O. Jorgensen, R.C. Cuneo, M.A. Boroujerdi, A. Cittadini, R. Napoli, J.S. Christiansen, B.A. Bengtsson, L. Sacca, R.C. Baxter, E.E. Basset, P.H. Sonksen The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J. Clin. Endocrinol. Metab. 2000, 85, 4193.
9. S. Longobardi, N. Keay, C. Ehrnborg, A. Cittadini, T. Rosen, R. Dall, M.A. Boroujerdi, E.E. Bassett, M.L. Healy, C. Pentecost, J.D. Wallace, J. Powrie, J.O. Jorgensen, L. Sacca Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J. Clin. Endocr. Metab. 2000, 85, 1505.
10. R.I. Holt, I. Erotokritou-Mulligan, C. McHugh, E.E. Bassett, C. Bartlett, A. Fityan, J.L. Bacon, D.A. Cowan, P.H. Sonksen The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. Eur. J. Endocrinol. 2010, 163, 45.
11. J.K. Powrie, E.E. Bassett, T. Rosen, J.O. Jorgensen, R. Napoli, L. Sacca, J.S. Christiansen, B.A. Bengtsson, P.H. Sonksen Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 2007, 17, 220.
12. W.H. Daughaday, K. Hall, M.S. Raben, W.D. Salmon Jr, J.L. van den Brande, J.J. van Wyk Somatomedin: proposed designation for sulphation factor. Nature 1972, 235(5333), 107.
13. N. Guha, I. Erotokritou-Mulligan, S.P. Nevitt, M. Francis, C. Bartlett, D.A. Cowan, E.E. Bassett, P.H. Sonksen, R.I.G. Holt Biochemical markers of IGF-I misuse: the response of IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) to the administration of recombinant human IGF-I/IGF binding protein-3 in recreational athletes. Growth Horm. IGF Res. 2012, 22, S20.
14. World Anti-Doping Agency (WADA). Guidelines for blood sample collection Version 2.3. Available at: http://www.wada-ama.org/Documents/Resources/Guidelines/WADA_Guidelines_Blood_sample_Collection_v2.3.pdf [20 April 2013].
15. K. Sjogren, J.L. Liu, K. Blad, S. Skrtic, O. Vidal, V. Wallenius, D. LeRoith, J. Tornell, O.G. Isaksson, J.O. Jansson, C. Ohlsson Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 7088.
16. S. Yakar, J.L. Liu, B. Stannard, A. Butler, D. Accili, B. Sauer, D. LeRoith Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 7324.
17. P.H. Sonksen Insulin, growth hormone and sport. J. Endocrinol. 2001, 170, 13.
18. P.V. Carroll, M. Umpleby, E.L. Alexander, V.A. Egel, K.V. Callison, P.H. Sonksen, D.L. Russell-Jones Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin. Endocrinol. 1998, 49, 739.
19. H.P. Guler, J. Zapf, C. Schmid, E.R. Froesch Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol.-Cop. 1989, 121, 753.
20. D.R. Clemmons, D.K. Snyder, W.H. Busby Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J. Clin. Endocr. Metab. 1991, 73, 727.
21. W.S. Cohick, M.A. McGuire, D.R. Clemmons, D.E. Bauman Regulation of insulin-like growth factor-binding proteins in serum and lymph of lactating cows by somatotropin. Endocrinology 1992, 130, 1508.
22. D.R. Clemmons, M. Sleevi, G. Allan, A. Sommer Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J. Clin. Endocr. Metab. 2007, 92, 2652.
23. M.E. Wilson Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys. J. Clin. Endocr. Metab. 2000, 85, 1557.
24. S.K. Grinspoon, H.B. Baum, S. Peterson, A. Klibanski Effects of rhIGF-I administration on bone turnover during short-term fasting. J. Clin. Invest. 1995, 96, 900.
25. B. Klinger, L.T. Jensen, A. Silbergeld, Z. Laron Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin. Endocrinol. 1996, 45, 423.
26. S. Boonen, C. Rosen, R. Bouillon, A. Sommer, M. McKay, D. Rosen, S. Adams, P. Broos, J. Lenaerts, J. Raus, D. Vanderschueren, P. Geusens Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J. Clin. Endocr. Metab. 2002, 87, 1593.
27. Food and Drug Administration (FDA). FDA Position on Allowing Patients with ALS Access to Iplex under an IND. Available at: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm118121.htm [10 March 2013].